BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 04, 2003
 |  BioCentury  |  Strategy

Shire: Back to the future

A company with six-month product sales of $502 million, four products in registration and three compounds in Phase III studies would appear to be headed in the right direction. But Shire Pharmaceuticals Group plc last week announced plans to drop its early stage R&D and return to its old model of in-licensing late stage products and acquiring companies in the $1 billion valuation bracket. The move is designed to get its EPS growth rate into the mid-teens.
Shire (LSE:SHP; SHPGY, Basingstoke, U.K.) switched gears in 2000 with the acquisition of BioChem Pharma Inc. (Laval, Quebec). In addition to adding royalties from the antiviral lamivudine, the transaction was designed to broaden the research base for SHP, which lacked extensive early stage R&D (see BioCentury, Dec. 18, 2000).The deal also added a Phase II project: Troxatyl, a dioxolane nucleoside analog in Phase II studies to treat acute myeloid leukemia and pancreatic cancer.
Indeed, most of SHP's current pipeline comes from external sources. Of SHP's four products in registration, only its Fosrenol lanthanum carbonate to reduce phosphate levels was developed internally. Adderall, already on...

Read the full 883 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >